Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.

about

Combination TS-1 plus EGFR-tyrosine kinase inhibitors (TKIs) for the treatment of non-small cell lung cancer after progression on first-line or further EGFR-TKIs: A phase II, single-arm trial.

P2860

Q52588501-CE5E26EB-54FC-4953-A99A-48E339ACE59B

P2860

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.

Item

http://www.wikidata.org/entity/Q54143053

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@en

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@nl

type

Item

label

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@en

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@nl

prefLabel

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@en

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@nl

P1476

Continuing EGFR-TKI beyond rad ...... ancer: an observational study.

@en

P2093

Akira Inoue

http://www.w3.org/2001/XMLSchema#string

Chiharu Tanai

http://www.w3.org/2001/XMLSchema#string

Hideo Kunitoh

http://www.w3.org/2001/XMLSchema#string

Hiroshi Isobe

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sakai

http://www.w3.org/2001/XMLSchema#string

Kazuhiko Yamada

http://www.w3.org/2001/XMLSchema#string

Kiyotaka Yoh

http://www.w3.org/2001/XMLSchema#string

Koichi Minato

http://www.w3.org/2001/XMLSchema#string

Makoto Nishio

http://www.w3.org/2001/XMLSchema#string

Takayuki Kaburagi

http://www.w3.org/2001/XMLSchema#string

P2860

Methodological issues in observational studies and non-randomized controlled trials in oncology in the era of big data.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

Comparative effectiveness research in oncology methodology: observational data.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

P304

e000214

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ESMOOPEN-2017-000214

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29018574

http://www.w3.org/2001/XMLSchema#string

P932

5604715

http://www.w3.org/2001/XMLSchema#string

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.

about

P2860

P2860

Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932